story of the week
Durvalumab Plus Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Radiotherapy in Metastatic NSCLC Refractory to Previous PD(L)-1 Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Lancet Oncol 2022 Jan 13;na(na)na, JD Schoenfeld, A Giobbie-Hurder, S Ranasinghe, KZ Kao, A Lako, J Tsuji, Y Liu, RC Brennick, RD Gentzler, C Lee, J Hubbard, SM Arnold, JL Abbruzzese, SK Jabbour, NV Uboha, KL Stephans, JM Johnson, H Park, LC Villaruz, E Sharon, H Streicher, MM Ahmed, H Lyon, C Cibuskis, N Lennon, A Jhaveri, L Yang, J Altreuter, L Gunasti, JL Weirather, RH Mak, MM Awad, SJ Rodig, HX Chen, CJ Wu, AM Monjazeb, FS HodiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.